Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

Core Viewpoint - Fresenius Medical Care (FME) has initiated the first tranche of its EUR 1 billion share buyback program, aimed at enhancing shareholder value as part of its new capital allocation framework [1][2][3]. Group 1: Share Buyback Program - The initial share buyback program totals EUR 1 billion over two years, with the first tranche of up to EUR 600 million set to be completed by April 30, 2026 [1][7]. - The share buyback is a key component of the FME Reignite strategy, which focuses on value creation for shareholders [2][3]. - Regular updates on the share buyback program will be provided on the company's investor relations website [3]. Group 2: Company Overview - Fresenius Medical Care is the leading provider of products and services for individuals with renal diseases, serving approximately 4.2 million patients globally who undergo dialysis treatment [4]. - The company operates a network of 3,676 dialysis clinics, providing treatments for around 300,000 patients worldwide [4]. - Fresenius Medical Care is also a major supplier of dialysis products, including dialysis machines and dialyzers, and is listed on both the Frankfurt Stock Exchange and the New York Stock Exchange [4].